размер рынка вакцин для путешествий, анализ доли и будущие тенденции к 2032 году

Q: What is the growth rate of the Travel Vaccine Market?

The Travel Vaccine Market growth rate is 8.9% by 2032. Read More

>Глобальный рынок вакцин для путешественников по составу (комбинированные вакцины и моновакцины), типу (инактивированные вакцины, субъединичные, рекомбинантные, полисахаридные и конъюгированные вакцины, живые ослабленные вакцины, анатоксины, ДНК-вакцины и вирусные векторные вакцины), категории (рекомендуемая вакцина, плановая вакцина и обязательная вакцина), заболеванию (брюшной тиф, гепатит, холера, ветряная оспа, грипп, японский энцефалит, менингококковый менингит, желтая лихорадка, бешенство, АКДС, корь и эпидемический паротит, клещевой энцефалит, малярия, COVID-19, полиомиелит и другие), способу введения (инъекционный и пероральный), полу (мужчина и женщина), типу пациента (взрослый, ребенок и пожилой), возрастной группе (20–50 лет, моложе 20 лет и Старше 50 лет), Канал сбыта (B2B и B2C) - Тенденции отрасли и прогноз до 2032 года.

Анализ и аналитика рынка вакцин для путешественников

С глобализацией и облегчением доступа к путешествиям все больше людей путешествуют по всему миру. Эта возросшая активность путешествий приводит к большей подверженности инфекционным заболеваниям, распространенным в разных регионах, что обуславливает спрос на туристические вакцины для защиты людей от заражения такими болезнями, как желтая лихорадка, брюшной тиф, гепатит А и другие. Хотя одним из основных ограничений для туристических вакцин является стоимость и доступность. Туристические вакцины могут быть дорогими, особенно для людей, которые могут путешествовать в несколько мест, требующих разных вакцинаций. Кроме того, доступ к медицинским услугам и клиникам вакцинации может быть ограничен в некоторых регионах, что затрудняет путешественникам получение необходимых прививок перед поездками. Достижения в области технологий вакцин, такие как разработка новых методов доставки или более эффективных производственных процессов, открывают возможности для повышения эффективности, доступности и ценовой доступности туристических вакцин. Такие инновации, как ДНК-вакцины, мРНК-вакцины или микроигольные пластыри, могут потенциально улучшить разработку и распространение туристических вакцин, сделав их более широкодоступными и экономически эффективными. Хотя нерешительность в отношении вакцин и дезинформация создают значительные проблемы для вакцин для путешественников. Некоторые люди могут не желать делать прививки из-за опасений по поводу безопасности, эффективности или неправильных представлений о болезнях, от которых они защищают. Борьба с нерешительностью в отношении вакцин и борьба с дезинформацией посредством образования, пропагандистских усилий и коммуникационных кампаний имеет решающее значение для того, чтобы путешественники понимали важность вакцин для защиты своего здоровья и предотвращения распространения инфекционных заболеваний через границы.

По данным исследования рынка Data Bridge, ожидается, что объем мирового рынка вакцин для путешественников к 2032 году достигнет 13,09 млрд долларов США по сравнению с 6,14 млрд долларов США в 2023 году, а среднегодовой темп роста составит 8,9% в прогнозируемый период с 2024 по 2032 год.

Отчет Метрика	Подробности
Прогнозируемый период	2024-2032
Базовый год	2023
Исторические годы	2022 (можно изменить на 2016–2021)
Количественные единицы	Доход в млрд долларов США
Охваченные сегменты	Состав (комбинированные вакцины и моновакцины), Тип (инактивированные вакцины, субъединичные, рекомбинантные, полисахаридные и конъюгированные вакцины , живые ослабленные вакцины, анатоксины, ДНК-вакцины и вирусные векторные вакцины), Категория (рекомендуемая вакцина, плановая вакцина и обязательная вакцина), Заболевание (брюшной тиф, гепатит, холера, ветряная оспа, грипп, японский энцефалит, менингококковый менингит, желтая лихорадка, бешенство, АКДС, корь и эпидемический паротит, клещевой энцефалит, малярия, COVID-19, полиомиелит и другие), Способ введения (инъекционный и пероральный), Пол (мужской и женский), Тип пациента (взрослый, ребенок и пожилой), Возрастная группа (20-50 лет, менее 20 лет и старше 50 лет), Канал дистрибуции (B2B и B2C)
Страны, охваченные	США, Канада, Мексика, Германия, Великобритания, Франция, Италия, Нидерланды, Испания, Россия, Швейцария, Польша, Норвегия, Венгрия, Австрия, Ирландия, Литва, остальные страны Европы, Китай, Япония, Индия, Южная Корея, Австралия, Сингапур, Таиланд, Индонезия, Малайзия, Филиппины, Вьетнам, остальные страны Азиатско-Тихоокеанского региона, Бразилия, Аргентина, Перу, остальные страны Южной Америки, Саудовская Аравия, ОАЭ, Израиль, Южная Африка, Египет, Кувейт и остальные страны Ближнего Востока и Африки
Охваченные участники рынка	GSK plc., Bavarian Nordic, Pfizer Inc., Abbott, CSL, AstraZeneca, Sanofi, Merck & Co., Inc., Valneva SE, Johnson & Johnson Services Inc. и Dynavax Technologies, среди прочих

Определение рынка

Туристические вакцины — это прививки, специально разработанные для защиты людей от инфекционных заболеваний, с которыми они могут столкнуться во время путешествий в разные регионы или страны. Эти вакцины вводятся перед отправлением в пункты назначения, где существует риск заражения болезнями, которые не распространены в родной стране или регионе человека. Типы рекомендуемых вакцин зависят от различных факторов, включая пункт назначения путешественника, продолжительность пребывания, запланированные мероприятия, текущее состояние здоровья и любые предыдущие прививки. Цель туристических вакцин — предотвратить распространение инфекционных заболеваний и обеспечить здоровье и безопасность путешественников во время их поездок.

Динамика мирового рынка вакцин для путешественников

В этом разделе рассматривается понимание движущих сил рынка, возможностей, ограничений и проблем. Все это подробно обсуждается ниже:

Драйверы

Рост заболеваемости инфекционными заболеваниями

Поскольку инфекционные заболевания распространяются или вновь возникают в различных частях мира, путешественники сталкиваются с повышенным риском воздействия этих патогенов во время своих поездок. Путешественники могут контактировать с инфекционными агентами через взаимодействие с местным населением, зараженную пищу или воду, укусы насекомых или воздействие опасностей окружающей среды. Повышенный риск заражения подчеркивает важность вакцинации как профилактической меры для защиты путешественников от потенциально серьезных или опасных для жизни заболеваний. Рост заболеваемости инфекционными заболеваниями стимулирует рост рынка вакцин для путешественников, увеличивая риск для путешественников, побуждая к обязательным требованиям вакцинации, реагируя на вспышки и эпидемии, продвигая профилактические меры в отношении эндемичных заболеваний и решая проблемы глобальной безопасности здравоохранения.

Правительственные постановления и рекомендации относительно вакцинации

Многие страны ввели обязательные требования вакцинации для путешественников, въезжающих на их территорию. Эти требования часто основаны на распространенности определенных заболеваний в определенных регионах и направлены на предотвращение ввоза и распространения инфекционных заболеваний. Например, страны Африки и Южной Америки могут потребовать доказательства вакцинации от желтой лихорадки для путешественников, прибывающих из регионов, где эта болезнь является эндемичной. Такие требования создают прямой спрос на вакцины для путешественников, которым необходимо соблюдать правила въезда .

Таким образом, правительственные постановления и рекомендации относительно вакцинации играют ключевую роль в стимулировании роста рынка вакцин для путешественников, создавая спрос, повышая осведомленность и облегчая доступ к услугам вакцинации для путешественников. Эти усилия имеют важное значение для защиты общественного здоровья и минимизации риска передачи заболеваний во время международных поездок.

Возможность

Достижения в области вакцинных технологий

Новые платформы вакцин, такие как вакцины мРНК и вирусные векторные вакцины, открывают новые возможности для разработки вакцин для путешественников. Эти инновационные платформы позволяют быстро разрабатывать и производить вакцины против широкого спектра патогенов, включая тех, которые ответственны за болезни, связанные с путешествиями. Используя новые платформы вакцин, исследователи могут ускорить разработку вакцин для путешественников следующего поколения с улучшенной эффективностью и более широким охватом против множества заболеваний.

Достижения в области вакцинных технологий позволяют разрабатывать вакцины с повышенной иммуногенностью, что приводит к более сильным и продолжительным иммунным реакциям. Новые адъюванты, системы доставки и стратегии разработки антигенов повышают эффективность вакцин, стимулируя надежные иммунные реакции и вызывая защитный иммунитет против целевых патогенов. Улучшая эффективность вакцин, технологические достижения повышают эффективность туристических вакцин в профилактике заболеваний и снижении риска заражения среди путешественников.

Ограничения / Проблемы

Cold Chain Requirements for Storage

Cold chain infrastructure, including refrigeration equipment, temperature monitoring devices, and storage facilities, is essential for maintaining vaccine potency during storage and transportation. However, many regions, particularly in low- and middle-income countries and remote areas, lack adequate cold chain infrastructure. The absence of reliable electricity, refrigeration facilities, and transportation networks complicates cold chain management and compromises vaccine storage conditions. As a result, vaccine distribution and access may be limited in regions with inadequate cold chain infrastructure, hindering the growth of the travel vaccine market.

Vaccines must be stored and transported within a specific temperature range to prevent heat or cold exposure that could compromise their efficacy. However, temperature fluctuations during transportation, such as exposure to extreme heat or freezing temperatures, can damage vaccines and render them ineffective. Ensuring temperature stability and monitoring during transit can be challenging, especially in regions with harsh environmental conditions or unreliable transportation systems. Temperature-sensitive vaccines, such as those requiring ultra-low temperature storage, face additional challenges in maintaining stability during transport, further complicating cold chain management and limiting vaccine accessibility.

High Cost of Travel Vaccines

For many individuals, especially those traveling on a budget or to low-income countries, the cost of travel vaccines can be prohibitive. Travelers may need to pay out-of-pocket for vaccines, as they are not always covered by health insurance plans. The cumulative cost of multiple vaccines recommended for travel to certain regions can add up quickly, leading some travelers to forgo vaccination altogether or to prioritize other travel expenses over vaccination. As a result, the high cost of travel vaccines may deter some individuals from seeking vaccination services, thereby limiting the growth of the travel vaccine market.

The high cost of travel vaccines exacerbates existing disparities in access to healthcare services. Individuals from marginalized or underserved communities, who may already face financial constraints in accessing healthcare, are disproportionately affected by the high cost of travel vaccines. This unequal access to vaccination services can contribute to gaps in vaccination coverage among travelers, particularly among those from low-income backgrounds. As a result, the growth of the travel vaccine market may be hindered by barriers to access imposed by the high cost of vaccines.

Recent Developments

In March 2024, Pfizer Inc. announced that the European Commission (EC) has granted marketing approval for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumonia in infants, children and adolescents from 6 weeks to less than 18 years of age
In October 2023, GSK plc. announced that it has reached an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to promote GSK's Zhifei vaccine in China for the first three years. Cooperation can be continued with the consent of all parties. Zhifei, China's largest vaccine company, has acquired innovative vaccines from China. By combining the scale and expertise of the two companies, the strategic partnership will significantly expand the availability of Shingrix, supporting rapid expansion of the vaccine to patients and future potential indications
In October 2022, Merck & Co., Inc., known as MSD outside the United States and Canada, declared today that the European Commission (EC) has approved an expanded indication for VAXNEUVANCE (15-valent pneumococcal conjugate vaccine), which includes active immunization for prevention. For the treatment of invasive disease, pneumonia and acute otitis media affected by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years. The approval facilitates the availability of VAXNEUVANCE to this population in all 27 member states of the European Union (EU), as well as in Iceland, Norway and Liechtenstein
In September 2022, AstraZeneca announces that doses of FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) are now available in the United States for the 2022-2023 influenza season. FLUMIST QUADRIVALENT, the only Food and Drug Administration (FDA)-approved nasal spray influenza vaccine, is indicated for ages 2 to 49.1 years. According to the 2022-2023 recommendations of the Immunization Practices Advisory Committee (ACIP) from Centers for Disease Control and Prevention (CDC). And the American Academy of Pediatrics (AAP), FLUMIST QUADRIVALENT remains an alternative to flu vaccination in the United States this season. The CDC emphasizes that the most effective protection against seasonal flu is the annual flu vaccine. This approval will help the company to expand their business
In February 2021, In February, Johnson & Johnson Services Inc. announced that the U.S. Food and Drug Administration (FDA) has delivered Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, established by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This has helped the company to strengthen its product portfolio

Global Travel Vaccine Market Scope

Глобальный рынок вакцин для путешественников сегментирован на девять заметных сегментов, которые основаны на составе, типе, категории, заболевании, пути введения, поле, типе пациента, возрастной группе и канале распространения. Рост среди сегментов помогает вам анализировать нишевые карманы роста и стратегии для выхода на рынок и определять ваши основные области применения и различия в ваших целевых рынках.

Состав

Комбинированные вакцины
Моновакцины

По составу рынок сегментируется на комбинированные вакцины и моновакцины.

Тип

Инактивированные вакцины
Субъединичные, рекомбинантные, полисахаридные и конъюгированные вакцины
Живые ослабленные вакцины
Анатоксиновые вакцины
ДНК-вакцины
Вакцины на основе вирусных векторов

По типу рынок сегментирован на инактивированные вакцины, субъединичные, рекомбинантные, полисахаридные и конъюгированные вакцины, живые ослабленные вакцины, анатоксины, ДНК-вакцины и вирусные векторные вакцины.

Категория

Рекомендуемая вакцина
Плановая вакцинация
Требуемая вакцина

По категориям рынок сегментируется на рекомендуемые вакцины, плановые вакцины и обязательные вакцины.

Болезнь

Брюшной тиф
Гепатит
Холера
Ветряная оспа
Грипп
Японский энцефалит
Менингококковый менингит
Желтая лихорадка
Бешенство
ДПТ
Корь и свинка
Клещевой энцефалит
Малярия
COVID-19
Полиомиелит
Другие

По типу заболевания рынок сегментирован на вакцины от брюшного тифа, гепатита, холеры, ветряной оспы, гриппа, японского энцефалита, менингококкового менингита, желтой лихорадки, бешенства, АКДС, кори и эпидемического паротита, клещевого энцефалита, малярии, COVID-19, полиомиелита и других.

Путь введения

Инъекционный
Оральный

По способу введения рынок сегментируется на инъекционные и пероральные.

Пол

Мужской
Женский

По половому признаку рынок сегментируется на мужской и женский.

Тип пациента

Взрослый
Педиатрический
гериатрический

В зависимости от типа пациента рынок сегментируется на взрослый, детский и гериатрический.

Возрастная группа

20-50 лет
Менее 20 лет
Старше 50 лет

По возрастному признаку рынок сегментируется на группы 20–50 лет, менее 20 лет и старше 50 лет.

Канал распространения

В2В
B2C

По каналу сбыта рынок сегментируется на B2B и B2C.

Региональный анализ/информация о мировом рынке вакцин для путешественников

Глобальный рынок вакцин для путешественников разделен на девять основных сегментов, которые различаются по составу, типу, категории, заболеванию, способу введения, полу, типу пациента, возрастной группе и каналу распространения.

В данном отчете о рынке рассматриваются следующие страны: США, Канада, Мексика, Германия, Великобритания, Франция, Италия, Нидерланды, Испания, Россия, Швейцария, Польша, Норвегия, Венгрия, Австрия, Ирландия, Литва, остальные страны Европы, Китай, Япония, Индия, Южная Корея, Австралия, Сингапур, Таиланд, Индонезия, Малайзия, Филиппины, Вьетнам, остальные страны Азиатско-Тихоокеанского региона, Бразилия, Аргентина, Перу, остальные страны Южной Америки, Саудовская Аравия, ОАЭ, Израиль, Южная Африка, Египет, Кувейт и остальные страны Ближнего Востока и Африки.

Ожидается, что Северная Америка будет доминировать на мировом рынке вакцин для путешественников с благоприятной политикой возмещения расходов на диализное лечение. Ожидается, что США будут доминировать в регионе Северной Америки из-за присутствия основных игроков рынка и улучшения развития и исследований в секторе здравоохранения. Ожидается, что Индия будет доминировать в Азиатско-Тихоокеанском регионе из-за своей огромной территории и большого количества гериатрических пациентов. Ожидается, что Германия будет доминировать в регионе Европы из-за своего внедрения передовых технологий, надежной инфраструктуры здравоохранения и зрелого рынка.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, заменяющие продажи, демографические данные страны, нормативные акты и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по стране учитываются наличие и доступность глобальных брендов и их проблемы, связанные с большой или малой конкуренцией со стороны местных и внутренних брендов, а также влияние каналов продаж.

Анализ конкурентной среды и доли мирового рынка вакцин для путешественников

Конкурентная среда мирового рынка вакцин для путешествий содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в НИОКР, новых рыночных инициативах, производственных площадках и объектах, сильных и слабых сторонах компании, запуске продукта, одобрении продукта, широте и широте продукта, доминировании приложений и жизненно важной кривой типа продукта. Приведенные выше данные касаются только фокуса компании на мировом рынке вакцин для путешествий.

К числу основных игроков, работающих на мировом рынке вакцин для путешественников, относятся GSK plc., Bavarian Nordic, Pfizer Inc., Abbott, CSL, AstraZeneca, Sanofi, Merck & Co., Inc., Valneva SE, Johnson & Johnson Services Inc. и Dynavax Technologies, а также другие.

SKU-52745

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Интерактивная панель анализа данных
Панель анализа компании для возможностей с высоким потенциалом роста
Доступ аналитика-исследователя для настройки и запросов
Анализ конкурентов с помощью интерактивной панели
Последние новости, обновления и анализ тенденций
Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов

Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL TRAVEL VACCINES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 PIPELINE ANALYSIS

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISING INCIDENCE OF INFECTIOUS DISEASES

5.1.2 INCREASING TRAVEL AND TOURISM

5.1.3 GOVERNMENT REGULATIONS AND RECOMMENDATIONS REGARDING VACCINATION

5.1.4 EXPANSION OF TRAVEL MEDICINE CLINICS

5.2 RESTRAINTS

5.2.1 HIGH COST OF TRAVEL VACCINES

5.2.2 REGULATORY HURDLES FOR APPROVAL

5.3 OPPORTUNITIES

5.3.1 ADVANCEMENTS IN VACCINE TECHNOLOGY

5.3.2 GROWING AWARENESS REGARDING VACCINES

5.3.3 INTEGRATION OF DIGITAL HEALTH SOLUTIONS

5.4 CHALLENGES

5.4.1 COLD CHAIN REQUIREMENTS FOR STORAGE

5.4.2 VACCINE HESITANCY AND MISINFORMATION

6 GLOBAL TRAVEL VACCINE MARKET, BY COMPOSITION

6.1 OVERVIEW

6.2 COMBINATION VACCINES

6.3 MONO VACCINES

7 GLOBAL TRAVEL VACCINE MARKET, BY TYPE

7.1 OVERVIEW

7.2 INACTIVATED VACCINES

7.2.1 HEPATITIS A

7.2.2 INFLUENZA

7.2.3 RABIES

7.2.4 TICK-BORNE ENCEPHALITIS

7.2.5 JAPANESE ENCEPHALITIS

7.2.6 POLIO

7.3 SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES

7.3.1 HEPATITIS B

7.3.2 MENINGOCOCCAL

7.3.3 MALARIA

7.3.4 COVID-19

7.4 LIVE-ATTENUATED VACCINES

7.4.1 TYPHOID

7.4.2 CHOLERA

7.4.3 YELLOW FEVER

7.4.4 MEASLES

7.4.5 MUMPS

7.4.6 RUBELLA

7.4.7 VARICELLA

7.4.8 OTHERS

7.5 TOXOID VACCINES

7.5.1 DIPHTHERIA

7.5.2 TETANUS

7.6 DNA VACCINES

7.7 VIRAL VECTOR VACCINES

8 GLOBAL TRAVEL VACCINE MARKET, BY CATEGORY

8.1 OVERVIEW

8.2 RECOMMENDED VACCINE

8.2.1 TYPHOID FEVER VACCINES

8.2.2 HEPATITIS A

8.2.3 CHOLERA

8.2.4 RABIES

8.2.5 TICK-BORNE ENCEPHALITIS

8.2.6 JAPANESE ENCEPHALITIS

8.2.7 MALARIA

8.2.8 OTHERS

8.3 ROUTINE VACCINE

8.3.1 HEPATITIS B

8.3.2 INFLUENZA VACCINES

8.3.3 PNEUMOCOCCAL

8.3.4 DIPHTHERIA

8.3.5 TETANUS

8.3.6 MEASLES

8.3.7 MUMPS

8.3.8 RUBELLA

8.3.9 PERTUSSIS

8.3.10 OTHERS

8.4 REQUIRED VACCINE

8.4.1 YELLOW FEVER

8.4.2 MENINGOCOCCAL

8.4.3 POLIO VACCINES

9 GLOBAL TRAVEL VACCINE MARKET, BY DISEASE

9.1 OVERVIEW

9.2 TYPHOID

9.3 HEPATITIS

9.3.1 HEPATITIS A

9.3.2 HEPATITIS B

9.4 CHOLERA

9.5 VARICELLA

9.6 INFLUENZA

9.7 JAPANESE ENCEPHALITIS

9.8 MENINGOCOCCAL MENINGITIS

9.9 YELLOW FEVER

9.1 RABIES

9.11 DPT

9.12 MEASLES AND MUMPS

9.13 TICK-BORNE ENCEPHALITIS

9.14 MALARIA

9.15 COVID-19

9.16 POLIO

9.17 OTHERS

10 GLOBAL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 INJECTABLE

10.2.1 INTRAMUSCULAR

10.2.2 SUBCUTANEOUS

10.2.3 OTHERS

10.3 ORAL

11 GLOBAL TRAVEL VACCINE MARKET, BY GENDER

11.1 OVERVIEW

11.2 MALE

11.3 FEMALE

12 GLOBAL TRAVEL VACCINE MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 ADULT

12.3 PEDIATRIC

12.4 GERIATRIC

13 GLOBAL TRAVEL VACCINE MARKET, BY AGE GROUP

13.1 OVERVIEW

13.2 20-50 YEARS

13.3 LESS THAN 20 YEARS

13.4 ABOVE 50 YEARS

14 GLOBAL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 B2B

14.3 B2C

15 GLOBAL TRAVEL VACCINE MARKET, BY REGION

15.1 OVERVIEW

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.2 CANADA

15.2.3 MEXICO

15.3 ASIA-PACIFIC

15.3.1 INDIA

15.3.2 CHINA

15.3.3 MALAYSIA

15.3.4 SOUTH KOREA

15.3.5 JAPAN

15.3.6 AUSTRALIA

15.3.7 THAILAND

15.3.8 VIETNAM

15.3.9 SINGAPORE

15.3.10 INDONESIA

15.3.11 PHILIPPINES

15.3.12 REST OF ASIA-PACIFIC

15.4 EUROPE

15.4.1 GERMANY

15.4.2 U.K.

15.4.3 FRANCE

15.4.4 RUSSIA

15.4.5 ITALY

15.4.6 SPAIN

15.4.7 POLAND

15.4.8 NETHERLANDS

15.4.9 SWITZERLAND

15.4.10 HUNGARY

15.4.11 AUSTRIA

15.4.12 IRELAND

15.4.13 NORWAY

15.4.14 LITHUANIA

15.4.15 REST OF EUROPE

15.5 MIDDLE EAST AND AFRICA

15.5.1 SAUDI ARABIA

15.5.2 EGYPT

15.5.3 SOUTH AFRICA

15.5.4 KUWAIT

15.5.5 U.A.E.

15.5.6 ISRAEL

15.5.7 REST OF MIDDLE EAST AND AFRICA

15.6 SOUTH AMERICA

15.6.1 ARGENTINA

15.6.2 BRAZIL

15.6.3 PERU

15.6.4 REST OF SOUTH AMERICA

16 GLOBAL TRAVEL VACCINE MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: GLOBAL

16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

16.3 COMPANY SHARE ANALYSIS: EUROPE

16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 PFIZER INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 SANOFI

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 JOHNSON & JOHNSON SERVICES INC.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 GSK PLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 MERCK & CO., INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBOTT

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ASTRAZENECA

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 BAVARIAN NORDIC

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENT

18.9 CSL

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.1 DYNAVAX TECHNOLOGIES.

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENTS

18.11 VALNEVA SE

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

Список таблиц

TABLE 1 PIPELINE ANALYSIS OF TRAVEL VACCINES MARKET

TABLE 2 VACCINES RECOMMENDATION FOR INTERNATIONAL TRAVELERS

TABLE 3 GLOBAL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 4 GLOBAL COMBINATION VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 5 GLOBAL MONO VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 6 GLOBAL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 7 GLOBAL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 8 GLOBAL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 9 GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 10 GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 11 GLOBAL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 12 GLOBAL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 13 GLOBAL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 14 GLOBAL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 15 GLOBAL DNA VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 16 GLOBAL VIRAL VECTOR VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 17 GLOBAL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 18 GLOBAL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 19 GLOBAL RECOMMENDED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 20 GLOBAL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 21 GLOBAL ROUTINE VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 22 GLOBAL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 23 GLOBAL REQUIRED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 24 GLOBAL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 25 GLOBAL TYPHOID IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 26 GLOBAL HEPATITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 27 GLOBAL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 28 GLOBAL CHOLERA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 29 GLOBAL VARICELLA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 30 GLOBAL INFLUENZA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 31 GLOBAL JAPANESE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 32 GLOBAL MENINGOCOCCAL MENINGITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 33 GLOBAL YELLOW FEVER IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 34 GLOBAL RABIES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 35 GLOBAL DPT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 36 GLOBAL MEASLES AND MUMPS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 37 GLOBAL TICK-BORNE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 38 GLOBAL MALARIA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 39 GLOBAL COVID-19 IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 40 GLOBAL POLIO IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 41 GLOBAL OTHERS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 42 GLOBAL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 43 GLOBAL INJECTABLE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 44 GLOBAL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 45 GLOBAL ORAL IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 46 GLOBAL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 47 GLOBAL MALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 48 GLOBAL FEMALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 49 GLOBAL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 50 GLOBAL ADULT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 51 GLOBAL PEDIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 52 GLOBAL GERIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 53 GLOBAL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 54 GLOBAL 20-50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 55 GLOBAL LESS THAN 20 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 56 GLOBAL ABOVE 50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 57 GLOBAL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 58 GLOBAL B2B IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 59 GLOBAL B2C IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 60 GLOBAL TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)

TABLE 61 NORTH AMERICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 62 NORTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 63 NORTH AMERICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 64 NORTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 65 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 66 NORTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 67 NORTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 68 NORTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 69 NORTH AMERICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 70 NORTH AMERICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 71 NORTH AMERICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 72 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 73 NORTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 74 NORTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 75 NORTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 76 NORTH AMERICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 77 NORTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 78 NORTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 79 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 80 U.S. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 81 U.S. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 82 U.S. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 83 U.S. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 84 U.S. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 85 U.S. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 86 U.S. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 87 U.S. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 88 U.S. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 89 U.S. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 90 U.S. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 91 U.S. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 92 U.S. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 93 U.S. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 94 U.S. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 95 U.S. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 96 U.S. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 97 U.S. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 98 CANADA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 99 CANADA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 100 CANADA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 101 CANADA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 102 CANADA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 103 CANADA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 104 CANADA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 105 CANADA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 106 CANADA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 107 CANADA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 108 CANADA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 109 CANADA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 110 CANADA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 111 CANADA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 112 CANADA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 113 CANADA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 114 CANADA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 115 CANADA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 116 MEXICO TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 117 MEXICO TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 118 MEXICO INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 119 MEXICO SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 120 MEXICO LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 121 MEXICO TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 122 MEXICO TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 123 MEXICO RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 124 MEXICO ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 125 MEXICO REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 126 MEXICO TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 127 MEXICO HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 128 MEXICO TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 129 MEXICO INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 130 MEXICO TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 131 MEXICO TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 132 MEXICO TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 133 MEXICO TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 134 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 135 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 136 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 137 ASIA-PACIFIC INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 138 ASIA-PACIFIC SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 139 ASIA-PACIFIC LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 140 ASIA-PACIFIC TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 141 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 142 ASIA-PACIFIC RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 143 ASIA-PACIFIC ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 144 ASIA-PACIFIC REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 145 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 146 ASIA-PACIFIC HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 147 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 148 ASIA-PACIFIC INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 149 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 150 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 151 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 152 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 153 INDIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 154 INDIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 155 INDIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 156 INDIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 157 INDIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 158 INDIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 159 INDIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 160 INDIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 161 INDIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 162 INDIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 163 INDIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 164 INDIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 165 INDIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 166 INDIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 167 INDIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 168 INDIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 169 INDIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 170 INDIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 171 CHINA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 172 CHINA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 173 CHINA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 174 CHINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 175 CHINA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 176 CHINA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 177 CHINA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 178 CHINA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 179 CHINA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 180 CHINA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 181 CHINA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 182 CHINA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 183 CHINA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 184 CHINA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 185 CHINA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 186 CHINA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 187 CHINA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 188 CHINA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 189 MALAYSIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 190 MALAYSIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 191 MALAYSIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 192 MALAYSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 193 MALAYSIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 194 MALAYSIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 195 MALAYSIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 196 MALAYSIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 197 MALAYSIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 198 MALAYSIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 199 MALAYSIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 200 MALAYSIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 201 MALAYSIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 202 MALAYSIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 203 MALAYSIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 204 MALAYSIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 205 MALAYSIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 206 MALAYSIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 207 SOUTH KOREA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 208 SOUTH KOREA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 209 SOUTH KOREA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 210 SOUTH KOREA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 211 SOUTH KOREA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 212 SOUTH KOREA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 213 SOUTH KOREA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 214 SOUTH KOREA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 215 SOUTH KOREA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 216 SOUTH KOREA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 217 SOUTH KOREA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 218 SOUTH KOREA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 219 SOUTH KOREA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 220 SOUTH KOREA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 221 SOUTH KOREA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 222 SOUTH KOREA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 223 SOUTH KOREA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 224 SOUTH KOREA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 225 JAPAN TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 226 JAPAN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 227 JAPAN INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 228 JAPAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 229 JAPAN LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 230 JAPAN TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 231 JAPAN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 232 JAPAN RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 233 JAPAN ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 234 JAPAN REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 235 JAPAN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 236 JAPAN HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 237 JAPAN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 238 JAPAN INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 239 JAPAN TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 240 JAPAN TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 241 JAPAN TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 242 JAPAN TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 243 AUSTRALIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 244 AUSTRALIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 245 AUSTRALIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 246 AUSTRALIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 247 AUSTRALIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 248 AUSTRALIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 249 AUSTRALIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 250 AUSTRALIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 251 AUSTRALIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 252 AUSTRALIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 253 AUSTRALIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 254 AUSTRALIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 255 AUSTRALIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 256 AUSTRALIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 257 AUSTRALIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 258 AUSTRALIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 259 AUSTRALIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 260 AUSTRALIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 261 THAILAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 262 THAILAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 263 THAILAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 264 THAILAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 265 THAILAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 266 THAILAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 267 THAILAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 268 THAILAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 269 THAILAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 270 THAILAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 271 THAILAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 272 THAILAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 273 THAILAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 274 THAILAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 275 THAILAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 276 THAILAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 277 THAILAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 278 THAILAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 279 VIETNAM TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 280 VIETNAM TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 281 VIETNAM INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 282 VIETNAM SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 283 VIETNAM LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 284 VIETNAM TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 285 VIETNAM TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 286 VIETNAM RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 287 VIETNAM ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 288 VIETNAM REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 289 VIETNAM TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 290 VIETNAM HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 291 VIETNAM TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 292 VIETNAM INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 293 VIETNAM TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 294 VIETNAM TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 295 VIETNAM TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 296 VIETNAM TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 297 SINGAPORE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 298 SINGAPORE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 299 SINGAPORE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 300 SINGAPORE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 301 SINGAPORE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 302 SINGAPORE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 303 SINGAPORE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 304 SINGAPORE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 305 SINGAPORE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 306 SINGAPORE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 307 SINGAPORE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 308 SINGAPORE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 309 SINGAPORE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 310 SINGAPORE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 311 SINGAPORE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 312 SINGAPORE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 313 SINGAPORE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 314 SINGAPORE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 315 INDONESIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 316 INDONESIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 317 INDONESIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 318 INDONESIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 319 INDONESIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 320 INDONESIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 321 INDONESIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 322 INDONESIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 323 INDONESIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 324 INDONESIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 325 INDONESIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 326 INDONESIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 327 INDONESIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 328 INDONESIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 329 INDONESIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 330 INDONESIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 331 INDONESIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 332 INDONESIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 333 PHILIPPINES TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 334 PHILIPPINES TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 335 PHILIPPINES INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 336 PHILIPPINES SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 337 PHILIPPINES LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 338 PHILIPPINES TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 339 PHILIPPINES TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 340 PHILIPPINES RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 341 PHILIPPINES ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 342 PHILIPPINES REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 343 PHILIPPINES TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 344 PHILIPPINES HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 345 PHILIPPINES TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 346 PHILIPPINES INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 347 PHILIPPINES TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 348 PHILIPPINES TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 349 PHILIPPINES TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 350 PHILIPPINES TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 351 REST OF ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 352 EUROPE TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 353 EUROPE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 354 EUROPE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 355 EUROPE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 356 EUROPE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 357 EUROPE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 358 EUROPE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 359 EUROPE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 360 EUROPE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 361 EUROPE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 362 EUROPE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 363 EUROPE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 364 EUROPE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 365 EUROPE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 366 EUROPE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 367 EUROPE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 368 EUROPE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 369 EUROPE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 370 EUROPE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 371 GERMANY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 372 GERMANY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 373 GERMANY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 374 GERMANY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 375 GERMANY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 376 GERMANY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 377 GERMANY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 378 GERMANY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 379 GERMANY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 380 GERMANY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 381 GERMANY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 382 GERMANY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 383 GERMANY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 384 GERMANY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 385 GERMANY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 386 GERMANY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 387 GERMANY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 388 GERMANY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 389 U.K. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 390 U.K. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 391 U.K. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 392 U.K. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 393 U.K. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 394 U.K. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 395 U.K. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 396 U.K. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 397 U.K. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 398 U.K. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 399 U.K. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 400 U.K. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 401 U.K. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 402 U.K. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 403 U.K. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 404 U.K. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 405 U.K. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 406 U.K. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 407 FRANCE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 408 FRANCE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 409 FRANCE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 410 FRANCE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 411 FRANCE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 412 FRANCE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 413 FRANCE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 414 FRANCE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 415 FRANCE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 416 FRANCE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 417 FRANCE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 418 FRANCE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 419 FRANCE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 420 FRANCE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 421 FRANCE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 422 FRANCE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 423 FRANCE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 424 FRANCE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 425 RUSSIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 426 RUSSIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 427 RUSSIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 428 RUSSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 429 RUSSIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 430 RUSSIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 431 RUSSIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 432 RUSSIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 433 RUSSIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 434 RUSSIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 435 RUSSIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 436 RUSSIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 437 RUSSIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 438 RUSSIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 439 RUSSIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 440 RUSSIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 441 RUSSIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 442 RUSSIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 443 ITALY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 444 ITALY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 445 ITALY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 446 ITALY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 447 ITALY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 448 ITALY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 449 ITALY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 450 ITALY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 451 ITALY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 452 ITALY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 453 ITALY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 454 ITALY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 455 ITALY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 456 ITALY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 457 ITALY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 458 ITALY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 459 ITALY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 460 ITALY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 461 SPAIN TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 462 SPAIN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 463 SPAIN INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 464 SPAIN SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 465 SPAIN LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 466 SPAIN TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 467 SPAIN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 468 SPAIN RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 469 SPAIN ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 470 SPAIN REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 471 SPAIN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 472 SPAIN HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 473 SPAIN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 474 SPAIN INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 475 SPAIN TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 476 SPAIN TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 477 SPAIN TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 478 SPAIN TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 479 POLAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 480 POLAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 481 POLAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 482 POLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 483 POLAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 484 POLAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 485 POLAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 486 POLAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 487 POLAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 488 POLAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 489 POLAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 490 POLAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 491 POLAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 492 POLAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 493 POLAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 494 POLAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 495 POLAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 496 POLAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 497 NETHERLANDS TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 498 NETHERLANDS TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 499 NETHERLANDS INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 500 NETHERLANDS SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 501 NETHERLANDS LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 502 NETHERLANDS TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 503 NETHERLANDS TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 504 NETHERLANDS RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 505 NETHERLANDS ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 506 NETHERLANDS REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 507 NETHERLANDS TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 508 NETHERLANDS HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 509 NETHERLANDS TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 510 NETHERLANDS INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 511 NETHERLANDS TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 512 NETHERLANDS TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 513 NETHERLANDS TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 514 NETHERLANDS TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 515 SWITZERLAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 516 SWITZERLAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 517 SWITZERLAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 518 SWITZERLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 519 SWITZERLAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 520 SWITZERLAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 521 SWITZERLAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 522 SWITZERLAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 523 SWITZERLAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 524 SWITZERLAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 525 SWITZERLAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 526 SWITZERLAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 527 SWITZERLAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 528 SWITZERLAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 529 SWITZERLAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 530 SWITZERLAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 531 SWITZERLAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 532 SWITZERLAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 533 HUNGARY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 534 HUNGARY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 535 HUNGARY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 536 HUNGARY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 537 HUNGARY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 538 HUNGARY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 539 HUNGARY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 540 HUNGARY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 541 HUNGARY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 542 HUNGARY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 543 HUNGARY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 544 HUNGARY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 545 HUNGARY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 546 HUNGARY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 547 HUNGARY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 548 HUNGARY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 549 HUNGARY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 550 HUNGARY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 551 AUSTRIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 552 AUSTRIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 553 AUSTRIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 554 AUSTRIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 555 AUSTRIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 556 AUSTRIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 557 AUSTRIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 558 AUSTRIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 559 AUSTRIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 560 AUSTRIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 561 AUSTRIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 562 AUSTRIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 563 AUSTRIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 564 AUSTRIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 565 AUSTRIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 566 AUSTRIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 567 AUSTRIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 568 AUSTRIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 569 IRELAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 570 IRELAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 571 IRELAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 572 IRELAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 573 IRELAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 574 IRELAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 575 IRELAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 576 IRELAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 577 IRELAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 578 IRELAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 579 IRELAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 580 IRELAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 581 IRELAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 582 IRELAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 583 IRELAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 584 IRELAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 585 IRELAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 586 IRELAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 587 NORWAY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 588 NORWAY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 589 NORWAY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 590 NORWAY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 591 NORWAY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 592 NORWAY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 593 NORWAY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 594 NORWAY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 595 NORWAY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 596 NORWAY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 597 NORWAY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 598 NORWAY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 599 NORWAY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 600 NORWAY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 601 NORWAY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 602 NORWAY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 603 NORWAY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 604 NORWAY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 605 LITHUANIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 606 LITHUANIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 607 LITHUANIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 608 LITHUANIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 609 LITHUANIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 610 LITHUANIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 611 LITHUANIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 612 LITHUANIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 613 LITHUANIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 614 LITHUANIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 615 LITHUANIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 616 LITHUANIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 617 LITHUANIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 618 LITHUANIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 619 LITHUANIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 620 LITHUANIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 621 LITHUANIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 622 LITHUANIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 623 REST OF EUROPE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 624 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 625 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 626 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 627 MIDDLE EAST AND AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 628 MIDDLE EAST AND AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 629 MIDDLE EAST AND AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 630 MIDDLE EAST AND AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 631 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 632 MIDDLE EAST AND AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 633 MIDDLE EAST AND AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 634 MIDDLE EAST AND AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 635 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 636 MIDDLE EAST AND AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 637 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 638 MIDDLE EAST AND AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 639 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 640 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 641 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 642 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 643 SAUDI ARABIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 644 SAUDI ARABIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 645 SAUDI ARABIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 646 SAUDI ARABIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 647 SAUDI ARABIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 648 SAUDI ARABIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 649 SAUDI ARABIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 650 SAUDI ARABIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 651 SAUDI ARABIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 652 SAUDI ARABIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 653 SAUDI ARABIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 654 SAUDI ARABIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 655 SAUDI ARABIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 656 SAUDI ARABIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 657 SAUDI ARABIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 658 SAUDI ARABIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 659 SAUDI ARABIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 660 SAUDI ARABIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 661 EGYPT TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 662 EGYPT TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 663 EGYPT INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 664 EGYPT SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 665 EGYPT LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 666 EGYPT TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 667 EGYPT TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 668 EGYPT RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 669 EGYPT ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 670 EGYPT REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 671 EGYPT TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 672 EGYPT HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 673 EGYPT TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 674 EGYPT INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 675 EGYPT TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 676 EGYPT TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 677 EGYPT TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 678 EGYPT TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 679 SOUTH AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 680 SOUTH AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 681 SOUTH AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 682 SOUTH AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 683 SOUTH AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 684 SOUTH AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 685 SOUTH AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 686 SOUTH AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 687 SOUTH AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 688 SOUTH AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 689 SOUTH AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 690 SOUTH AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 691 SOUTH AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 692 SOUTH AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 693 SOUTH AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 694 SOUTH AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 695 SOUTH AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 696 SOUTH AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 697 KUWAIT TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 698 KUWAIT TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 699 KUWAIT INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 700 KUWAIT SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 701 KUWAIT LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 702 KUWAIT TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 703 KUWAIT TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 704 KUWAIT RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 705 KUWAIT ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 706 KUWAIT REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 707 KUWAIT TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 708 KUWAIT HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 709 KUWAIT TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 710 KUWAIT INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 711 KUWAIT TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 712 KUWAIT TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 713 KUWAIT TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 714 KUWAIT TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 715 U.A.E. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 716 U.A.E. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 717 U.A.E. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 718 U.A.E. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 719 U.A.E. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 720 U.A.E. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 721 U.A.E. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 722 U.A.E. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 723 U.A.E. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 724 U.A.E. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 725 U.A.E. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 726 U.A.E. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 727 U.A.E. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 728 U.A.E. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 729 U.A.E. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 730 U.A.E. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 731 U.A.E. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 732 U.A.E. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 733 ISRAEL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 734 ISRAEL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 735 ISRAEL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 736 ISRAEL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 737 ISRAEL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 738 ISRAEL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 739 ISRAEL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 740 ISRAEL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 741 ISRAEL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 742 ISRAEL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 743 ISRAEL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 744 ISRAEL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 745 ISRAEL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 746 ISRAEL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 747 ISRAEL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 748 ISRAEL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 749 ISRAEL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 750 ISRAEL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 751 REST OF MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 752 SOUTH AMERICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)

TABLE 753 SOUTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 754 SOUTH AMERICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 755 SOUTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 756 SOUTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 757 SOUTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 758 SOUTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 759 SOUTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 760 SOUTH AMERICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 761 SOUTH AMERICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 762 SOUTH AMERICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 763 SOUTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 764 SOUTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 765 SOUTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 766 SOUTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 767 SOUTH AMERICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 768 SOUTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 769 SOUTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 770 SOUTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 771 ARGENTINA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 772 ARGENTINA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 773 ARGENTINA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 774 ARGENTINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 775 ARGENTINA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 776 ARGENTINA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 777 ARGENTINA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 778 ARGENTINA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 779 ARGENTINA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 780 ARGENTINA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 781 ARGENTINA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 782 ARGENTINA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 783 ARGENTINA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 784 ARGENTINA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 785 ARGENTINA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 786 ARGENTINA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 787 ARGENTINA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 788 ARGENTINA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 789 BRAZIL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 790 BRAZIL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 791 BRAZIL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 792 BRAZIL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 793 BRAZIL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 794 BRAZIL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 795 BRAZIL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 796 BRAZIL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 797 BRAZIL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 798 BRAZIL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 799 BRAZIL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 800 BRAZIL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 801 BRAZIL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 802 BRAZIL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 803 BRAZIL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 804 BRAZIL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 805 BRAZIL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 806 BRAZIL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 807 PERU TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

TABLE 808 PERU TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 809 PERU INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 810 PERU SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 811 PERU LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 812 PERU TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)

TABLE 813 PERU TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 814 PERU RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 815 PERU ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 816 PERU REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)

TABLE 817 PERU TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 818 PERU HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)

TABLE 819 PERU TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 820 PERU INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)

TABLE 821 PERU TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)

TABLE 822 PERU TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)

TABLE 823 PERU TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)

TABLE 824 PERU TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)

TABLE 825 REST OF SOUTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)

Список рисунков

FIGURE 1 GLOBAL TRAVEL VACCINES MARKET: SEGMENTATION

FIGURE 2 GLOBAL TRAVEL VACCINES MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL TRAVEL VACCINES MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL TRAVEL VACCINES MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL TRAVEL VACCINES MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL TRAVEL VACCINES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL TRAVEL VACCINES MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL TRAVEL VACCINES MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 GLOBAL TRAVEL VACCINES MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL TRAVEL VACCINES MARKET: SEGMENTATION

FIGURE 11 RISING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION AMONG TRAVELERS ARE EXPECTED TO DRIVE THE GLOBAL TRAVEL VACCINES MARKET IN THE FORECAST PERIOD OF 2024 TO 2032

FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL TRAVEL VACCINES MARKET IN 2021 & 2032

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE AND THE GLOBAL TRAVEL VACCINES MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2032

FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR TRAVEL VACCINES MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2032

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL TRAVEL VACCINE MARKET

FIGURE 16 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, 2023

FIGURE 17 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, 2024-2032 (USD THOUSAND)

FIGURE 18 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION , CAGR (2024-2032)

FIGURE 19 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, LIFELINE CURVE

FIGURE 20 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, 2023

FIGURE 21 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, 2024-2032 (USD THOUSAND)

FIGURE 22 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, CAGR (2024-2032)

FIGURE 23 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, 2023

FIGURE 25 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, 2024-2032 (USD THOUSAND)

FIGURE 26 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, CAGR (2024-2032)

FIGURE 27 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, LIFELINE CURVE

FIGURE 28 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, 2023

FIGURE 29 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, 2024-2032 (USD THOUSAND)

FIGURE 30 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, CAGR (2024-2032)

FIGURE 31 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, LIFELINE CURVE

FIGURE 32 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 33 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2032 (USD THOUSAND)

FIGURE 34 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2032)

FIGURE 35 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, 2023

FIGURE 37 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, 2024-2032 (USD THOUSAND)

FIGURE 38 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, CAGR (2024-2032)

FIGURE 39 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, LIFELINE CURVE

FIGURE 40 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2023

FIGURE 41 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2024-2032 (USD THOUSAND)

FIGURE 42 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, CAGR (2024-2032)

FIGURE 43 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 44 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, 2023

FIGURE 45 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, 2024-2032 (USD THOUSAND)

FIGURE 46 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, CAGR (2024-2032)

FIGURE 47 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 48 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 49 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2024-2032 (USD THOUSAND)

FIGURE 50 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2032)

FIGURE 51 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 52 GLOBAL TRAVEL VACCINE MARKET: SNAPSHOT (2023)

FIGURE 53 GLOBAL TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)

FIGURE 54 NORTH AMERICA TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)

FIGURE 55 EUROPE TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)

FIGURE 56 AISA-PACIFIC TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)

View Detailed Information

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

How big is the Travel Vaccine Market?

The Travel Vaccine Market size will be worth USD 13.09 billion by 2032.

What is the growth rate of the Travel Vaccine Market?

The Travel Vaccine Market growth rate is 8.9% by 2032.

What are the growth drivers of the Travel Vaccine Market?

Rising Incidence of Infectious Diseases, Government Regulations and Recommendations Regarding Vaccination are the growth drivers of the Travel Vaccine Market.

What are the factors on which the Travel Vaccine Market research is based on?

The composition, type, category, disease, route of administration, gender, patient type, age group, and distribution channel are the factors on which the Travel Vaccine Market research is based.

Which are the major companies in the Travel Vaccine Market?

The major companies in the Travel Vaccine Market are GSK plc., Bavarian Nordic, Pfizer Inc., Abbott, CSL, AstraZeneca, Sanofi, Merck & Co., Inc., Valneva SE, Johnson & Johnson Services Inc., and Dynavax Technologies.

Глобальный рынок вакцин для путешественников – тенденции отрасли и прогноз до 2032 года

Глобальный рынок вакцин для путешественников – тенденции отрасли и прогноз до 2032 года

Анализ и аналитика рынка вакцин для путешественников

Динамика мирового рынка вакцин для путешественников

Global Travel Vaccine Market Scope

Региональный анализ/информация о мировом рынке вакцин для путешественников

Анализ конкурентной среды и доли мирового рынка вакцин для путешественников

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Отчеты

Обзор рынка

Поддерживать

Решения

Глобальный рынок вакцин для путешественников – тенденции отрасли и прогноз до 2032 года

Глобальный рынок вакцин для путешественников – тенденции отрасли и прогноз до 2032 года

Анализ и аналитика рынка вакцин для путешественников

Динамика мирового рынка вакцин для путешественников

Global Travel Vaccine Market Scope

Региональный анализ/информация о мировом рынке вакцин для путешественников

Анализ конкурентной среды и доли мирового рынка вакцин для путешественников

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Просмотр связанных страниц